Effects of ibrutinib and venetoclax on the expression of immune checkpoint molecules in leukemic blasts of patients with acute lymphoblastic leukemia
Background: In recent decades, targeted therapy using small molecule inhibitors (SMI) have been shown very promising results in the treatment of a variety of solid and hematopoietic malignancies. However, their exact mechanisms, especiallay on the evasion strategies of tumor cells from the host immu...
Saved in:
| Main Authors: | Armin Dozandeh-Jouybari, Fatemeh Mousavi-Mirkalaei, Saeid Taghiloo, Hossein Karami, Mohammad Naderisorki, Ehsan Zaboli, Mohammad Eslami-Jouybari, Tohid Kazemi, Hossein Asgarian-Omran |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | Biochemistry and Biophysics Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405580825001323 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Preventing and managing the toxicities associated with the combination therapy of ibrutinib and venetoclax in chronic lymphocytic leukaemia
by: Elżbieta Iskierka-Jażdżewska, et al.
Published: (2025-01-01) -
SUCCESSFUL LONG-TERM REMISSION IN AGGRESSIVE YOUNG-ONSET CHRONIC LYMPHOCYTIC LEUKEMIA WITH IBRUTINIB AND VENETOCLAX: A DECADE-LONG CASE STUDY
by: Naciye Nur Tozluklu, et al.
Published: (2024-12-01) -
Paraneoplastic myelitis associated with Waldenström macroglobulinemia responsive to treatment with ibrutinib – venetoclax: A case report
by: Sathya Narasimhan, et al.
Published: (2024-12-01) -
İbrutinib Sonrası Gelişen Dev Ekimoz ve Hematom: Olgu Sunumu
by: Aynur Uğur Bilgin, et al.
Published: (2017-03-01) -
RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: CHEMOIMMUNOTHERAPY, TREATMENT UNTIL PROGRESSION WITH MECHANISM-DRIVEN AGENTS OR FINITE-DURATION THERAPY?
by: Antonio Cuneo, et al.
Published: (2019-02-01)